Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

Bernstein analyst Jeffrey Walch maintained a Hold rating on Incyte yesterday and set a price target of $104.00. The company’s shares closed yesterd...

Incyte (INCY) Gets a Hold from Bernstein

Insiders have been trading these 5 stocks: (($AFL)), (($CME)), (($INCY)), (($BOX)) and (($FIVE)). Here is a breakdown of their recent trades and th...

AFLAC, CME, Incyte, Box, Five Below Insider Shake-Up

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY) and Revolution Medicines (RVMD). Inc...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Revolution Medicines (RVMD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LL...

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

An announcement from Incyte ( ($INCY) ) is now available. Incyte Corporation said it has entered into an agreement with the U.S. Centers for Medica...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INCY	$123.89	-0.44%	1.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INCY	$123.89	-0.4%	1.21M
3
4
5
6

INCY

Get Incyte Corporation Data in Excel

Get Incyte Corporation Data in Excel